CY2015018I2 - Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων - Google Patents

Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων

Info

Publication number
CY2015018I2
CY2015018I2 CY2015018C CY2015018C CY2015018I2 CY 2015018 I2 CY2015018 I2 CY 2015018I2 CY 2015018 C CY2015018 C CY 2015018C CY 2015018 C CY2015018 C CY 2015018C CY 2015018 I2 CY2015018 I2 CY 2015018I2
Authority
CY
Cyprus
Prior art keywords
kdr
human antibodies
antibodies specific
specific
human
Prior art date
Application number
CY2015018C
Other languages
English (en)
Other versions
CY2015018I1 (el
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27805075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2015018(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of CY2015018I2 publication Critical patent/CY2015018I2/el
Publication of CY2015018I1 publication Critical patent/CY2015018I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
CY2015018C 2002-03-04 2015-04-30 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων CY2015018I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36178302P 2002-03-04 2002-03-04
EP03711375A EP1487856B1 (en) 2002-03-04 2003-03-04 Human antibodies specific to kdr and uses thereof

Publications (2)

Publication Number Publication Date
CY2015018I2 true CY2015018I2 (el) 2016-04-13
CY2015018I1 CY2015018I1 (el) 2016-04-13

Family

ID=27805075

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20101100793T CY1111141T1 (el) 2002-03-04 2010-08-30 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
CY20111100630T CY1111629T1 (el) 2002-03-04 2011-06-29 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
CY2015018C CY2015018I1 (el) 2002-03-04 2015-04-30 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20101100793T CY1111141T1 (el) 2002-03-04 2010-08-30 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
CY20111100630T CY1111629T1 (el) 2002-03-04 2011-06-29 Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων

Country Status (18)

Country Link
US (2) US7498414B2 (el)
EP (3) EP1487856B1 (el)
JP (3) JP2005526506A (el)
AT (2) ATE475431T1 (el)
AU (1) AU2003213687A1 (el)
BE (1) BE2015C027I2 (el)
CA (1) CA2478169C (el)
CY (3) CY1111141T1 (el)
DE (1) DE60333554D1 (el)
DK (2) DK1487856T3 (el)
ES (2) ES2347543T3 (el)
FR (1) FR15C0034I2 (el)
HK (1) HK1118229A1 (el)
HU (1) HUS1500025I1 (el)
LU (1) LU92710I2 (el)
PT (2) PT1916001E (el)
SI (2) SI1487856T1 (el)
WO (1) WO2003075840A2 (el)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213687A1 (en) * 2002-03-04 2003-09-22 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
KR101374514B1 (ko) * 2003-12-10 2014-03-13 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
CA2553946C (en) * 2004-02-06 2019-02-26 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
EP1735348B1 (en) 2004-03-19 2012-06-20 Imclone LLC Human anti-epidermal growth factor receptor antibody
PL1737891T3 (pl) * 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
KR101404512B1 (ko) 2005-01-05 2015-01-29 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을갖는 합성 면역글로불린 영역
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
AU2006267097A1 (en) * 2005-07-13 2007-01-18 Beth Israel Deaconess Medical Center Methods of diagnosing and treating an inflammatory response
CN101370519B (zh) * 2005-12-15 2013-07-24 阿斯利康(瑞典)有限公司 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP2727936B1 (en) 2006-11-22 2016-09-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
AU2008252854A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
US10214588B2 (en) * 2007-07-03 2019-02-26 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
WO2009013543A2 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to kdr and uses thereof - 035
UY31478A1 (es) 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20120183547A1 (en) * 2009-05-27 2012-07-19 Mount Sinai School Of Medicine Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
AU2010343193A1 (en) * 2009-12-29 2012-06-21 Yale University Inhibitors of vascular endothelial growth factor (VEGF) receptors and methods of use thereof
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CN103180339B (zh) 2010-05-26 2016-04-27 百时美施贵宝公司 具有改善的稳定性的基于纤连蛋白的支架蛋白质
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
CA2837527C (en) 2011-06-02 2019-05-28 Dyax Corp. Fc receptor binding proteins
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2707251C2 (ru) 2011-10-03 2019-11-25 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
WO2013067098A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2833892A4 (en) 2012-04-02 2016-07-20 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
EA032679B1 (ru) * 2012-10-05 2019-07-31 Кадмон Корпорейшн, Ллк Человеческие анти-vegfr-2/kdr-антитела
CA2892193C (en) 2012-11-21 2018-06-19 Pharmabcine Inc. Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including the same
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
ES2774964T3 (es) 2013-02-04 2020-07-23 Vascular Biogenics Ltd Métodos para inducir la capacidad de respuesta a un agente antiangiogénico
ES2771478T3 (es) 2013-02-18 2020-07-06 Vegenics Pty Ltd Moléculas de unión a ligando y usos de las mismas
US9618523B2 (en) * 2013-02-28 2017-04-11 Siemens Healthcare Diagnostics Inc. Methods and reagents for determining isomeric analytes
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
TWI558399B (zh) * 2014-02-26 2016-11-21 美國禮來大藥廠 癌症之組合療法
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
KR20170003692A (ko) 2014-05-15 2017-01-09 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
TWI569808B (zh) 2014-08-15 2017-02-11 禮來大藥廠 肝細胞腫瘤（ｈｃｃ）之治療
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
EA036257B1 (ru) * 2014-10-07 2020-10-20 КАДМОН КОРПОРЕЙШН, ЭлЭлСи Антитела человека против vegfr-2/kdr
TW201625304A (zh) 2014-10-24 2016-07-16 美國禮來大藥廠 泌尿上皮癌之療法
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
ES2855798T3 (es) 2015-07-14 2021-09-24 Bristol Myers Squibb Co Método de tratamiento del cáncer usando un inhibidor de puntos de control inmunitario; anticuerpo que se une al receptor de muerte programada 1 (pd-1) o al ligando de muerte programada 1 (pd-l1)
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
WO2017117384A1 (en) * 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
JP2019511541A (ja) 2016-04-15 2019-04-25 イーライ リリー アンド カンパニー 結腸直腸癌の処置における使用のためのラムシルマブとメレスチニブとの組み合わせ
WO2017180461A1 (en) 2016-04-15 2017-10-19 Eli Lilly And Company Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma
JP7169195B2 (ja) 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
US20190183972A1 (en) 2016-06-03 2019-06-20 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
US20200062850A1 (en) 2016-10-28 2020-02-27 Imclone Llc Combination of an anti-vegfr-2 antibody and an anti-pd-l1 antibody for the treatment of cancer
BR112019010349A2 (pt) * 2016-11-23 2019-10-08 Bioverativ Therapeutics Inc Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
CN106674349B (zh) 2017-03-07 2018-03-13 北京东方百泰生物科技有限公司 一种改进的抗vegfr‑2单克隆抗体
WO2019040348A1 (en) 2017-08-21 2019-02-28 Eli Lilly And Company COMBINATIONS OF EGFR INHIBITORS AND ANTI-VEGFR -2 HUMAN ANTIBODIES
WO2019077593A1 (en) 2017-10-20 2019-04-25 Vascular Biogenics Ltd. DIAGNOSTIC METHODS FOR ANTI-ANGIOGENIC AGENT TREATMENT
EP3813880A4 (en) 2018-06-29 2022-07-13 Gensun Biopharma Inc. ANTITUMORS IMMUNOTEST POINT REGULATOR ANTAGONISTS
WO2020106886A1 (en) 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
AU2020234098A1 (en) 2019-03-13 2021-09-16 Vascular Biogenics Ltd. Methods of anti-tumor therapy
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
WO2021020979A1 (en) 2019-07-31 2021-02-04 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN111024949A (zh) * 2019-12-31 2020-04-17 上海博威生物医药有限公司 一种重组抗vegfr2单克隆抗体的生物活性分析方法及其应用
AU2021337223A1 (en) 2020-09-02 2023-03-16 Msd International Gmbh Combination therapy of a PD-1 antagonist and an antagonist for VEGFR-2 for treating patients with cancer
CN114316064A (zh) * 2020-10-10 2022-04-12 广东菲鹏制药股份有限公司 融合蛋白及其应用
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328695A (en) * 1983-03-22 1994-07-12 Massachusetts Institute Of Technology Muscle morphogenic protein and use thereof
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4683295A (en) * 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5674722A (en) * 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE4103975A1 (de) 1991-02-09 1992-08-13 Thomson Brandt Gmbh Verfahren zur verkuerzung der zugriffszeit
SK281142B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
US20010021382A1 (en) * 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5543503A (en) * 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
ES2193143T3 (es) * 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5693482A (en) * 1992-07-27 1997-12-02 California Institute Of Technology Neural chest stem cell assay
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5837242A (en) * 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
JP3670302B2 (ja) * 1993-07-23 2005-07-13 ファナック株式会社 射出成形機における可塑化の管理方法
US5599703A (en) * 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
AT402796B (de) * 1995-02-01 1997-08-25 Fritschi Apparatebau Schibindung
US5843633A (en) * 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
JP3658471B2 (ja) * 1996-09-30 2005-06-08 株式会社日立製作所 電子ショッピングシステムにおける買物かご機能の提示方法及び電子ショッピングシステム
WO1998022616A1 (fr) * 1996-11-21 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal avec recepteur f1t-1 vegf anti-humain
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
WO1998058053A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
PL348634A1 (en) 1998-05-15 2002-06-03 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
ATE348629T1 (de) * 1999-01-15 2007-01-15 Medstar Res Inst Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1
IL144578A0 (en) 1999-01-29 2002-05-23 Imclone Systems Inc Antibodies specific to kdr and uses thereof
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
SK15302002A3 (sk) 2000-03-31 2004-06-08 Imclone Systems Incorporated Antagonista receptora VEGFR a jeho použitie
JP2004511430A (ja) * 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド 二重特異性免疫グロブリン様抗原結合蛋白および製造方法
JP2005508298A (ja) 2001-06-20 2005-03-31 イムクローン システムズ インコーポレイティド アテローム性動脈硬化症及び他の炎症性疾患を処置する方法
CA2452058A1 (en) 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US6519852B1 (en) * 2001-07-26 2003-02-18 Yuecom Manufacturing Co., Ltd. Method of manufacturing an aluminum alloy wheel rim
AU2003213687A1 (en) * 2002-03-04 2003-09-22 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US6844779B2 (en) * 2003-06-19 2005-01-18 The United States Of America As Represented By The Secretary Of The Air Force Optically isolated bias control circuit

Also Published As

Publication number Publication date
US20090142358A1 (en) 2009-06-04
EP1487856A2 (en) 2004-12-22
AU2003213687A1 (en) 2003-09-22
PT1487856E (pt) 2010-09-29
JP2009148298A (ja) 2009-07-09
JP2012105667A (ja) 2012-06-07
PT1916001E (pt) 2011-07-18
CA2478169C (en) 2013-04-16
JP4970483B2 (ja) 2012-07-04
BE2015C027I2 (el) 2022-05-19
US8057791B2 (en) 2011-11-15
EP2298346A2 (en) 2011-03-23
ATE475431T1 (de) 2010-08-15
FR15C0034I1 (fr) 2015-06-26
EP1916001B1 (en) 2011-05-25
EP1916001A3 (en) 2008-08-13
HUS1500025I1 (hu) 2017-04-28
WO2003075840A2 (en) 2003-09-18
EP2298346A3 (en) 2011-11-16
WO2003075840A3 (en) 2004-04-29
DE60333554D1 (de) 2010-09-09
ES2347543T3 (es) 2010-11-02
DK1916001T3 (da) 2011-07-18
SI1916001T1 (sl) 2011-10-28
CY1111141T1 (el) 2015-06-11
CA2478169A1 (en) 2003-09-18
LU92710I2 (fr) 2015-11-02
US20050234225A1 (en) 2005-10-20
FR15C0034I2 (fr) 2016-08-26
SI1487856T1 (sl) 2010-12-31
CY1111629T1 (el) 2015-10-07
ATE510561T1 (de) 2011-06-15
ES2362931T3 (es) 2011-07-15
EP1487856B1 (en) 2010-07-28
HK1118229A1 (en) 2009-02-06
JP2005526506A (ja) 2005-09-08
DK1487856T3 (da) 2010-10-18
EP1487856A4 (en) 2006-08-23
US7498414B2 (en) 2009-03-03
EP1916001A2 (en) 2008-04-30
JP5476404B2 (ja) 2014-04-23
AU2003213687A8 (en) 2003-09-22
CY2015018I1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
CY2015018I2 (el) Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
CY2017045I1 (el) Αντισωματα ειδικα για το cd22 και η θεραπευτικη και διαγνωστικη χρηση τους
CY2019018I1 (el) Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY2018009I1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
CY2019022I1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
CY2014037I2 (el) C-met διαμορφωτες και μεθοδοι χρησης
IS7668A (is) Manngerð mótefni gegn 4-1BB í mönnum
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
CY2014001I1 (el) Συνδυασμος αζελαστινης και φλουτικαζονης
IS8266A (is) Breytt mennsk IGF-1R mótefni
NO20054170D0 (no) Antistoff mot human IL-21 reseptor og anvendelser derav
DK1572946T3 (da) Terapeutisk humant monoklonalt anti-IL-1R1-antistof
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
DE60324178D1 (de) THIAZOLIDIN-4-ONES UM hYAK3 PROTEINEN ZU HEMMEN
DE60216254D1 (de) Acrylkautschukzusammensetzung und vulkanisat
NO20041802L (no) Antistoffer mot human vevsfaktor
DE60304645D1 (de) Hautpflegemittel enthaltend Octylmethoxycinnamat
DE60315473D1 (de) Acrylkautschukzusammensetzung und vernetztes produkt
NO20044106L (no) Omkonstruerte baculoviruser og anvendelse derav
IS7902A (is) Blettaeyðandi samsetning fyrir húðumhirðu
EE200200531A (et) Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
FR2850276B1 (fr) Composition anti-exsudante et/ou anti-desquamante et/ou anti-exfoliante
SE0202256D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XVI